Bristol Myers’ Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval

All NewsDecember 5, 2025

FDA approves Breyanzi, a CAR T cell therapy for relapsed or refractory marginal zone lymphoma. It has a high response rate.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent